Home Cart Sign in  
Chemical Structure| 475489-16-8 Chemical Structure| 475489-16-8

Structure of NVP-AEW541
CAS No.: 475489-16-8

Chemical Structure| 475489-16-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NVP-AEW541 (AEW541) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 of 0.15 μM. It also inhibits the insulin receptor (InsR) with an IC50 of 0.14 μM, showcasing significant antitumor activity.

Synonyms: AEW541

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NVP-AEW541

CAS No. :475489-16-8
Formula : C27H29N5O
M.W : 439.55
SMILES Code : NC1=C2C(N([C@@H]3C[C@@H](C3)CN4CCC4)C=C2C5=CC=CC(OCC6=CC=CC=C6)=C5)=NC=N1
Synonyms :
AEW541
MDL No. :MFCD22741515

Safety of NVP-AEW541

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of NVP-AEW541

RTK

Isoform Comparison

Biological Activity

Description
NVP-AEW541 (AEW541) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 of 0.15 μM. It also inhibits the insulin receptor (InsR) with an IC50 of 0.14 μM, showcasing significant antitumor activity[1].
Target
  • IGF-1R

    IGF-1R, IC50:0.15 μM

  • Insulin Receptor

    Insulin Receptor, IC50:0.14 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
HT29 0.1 µM 24 hours To evaluate the effect of NVP-AEW541 on IGF-1R nuclear localization, results showed that NVP-AEW541 did not significantly increase IGF-1R nuclear localization PMC5729466
HT29-OxR 0.1 µM 24 hours To evaluate the effect of NVP-AEW541 on IGF-1R nuclear localization, results showed that NVP-AEW541 did not significantly increase IGF-1R nuclear localization PMC5729466
5-8F OE cells 10μM 48 hours To evaluate the effect of NVP-AEW541 on cell proliferation, results showed that NVP-AEW541 effectively inhibited the proliferation of 5-8F OE cells. PMC10860326
BM3 cells 10μM 48 hours To evaluate the effect of NVP-AEW541 on cell proliferation, results showed that NVP-AEW541 effectively inhibited the proliferation of BM3 cells. PMC10860326

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice nasopharyngeal carcinoma bone metastasis model oral 25 µM Media were replaced every 48 hours, continued for 4 weeks To evaluate the effect of NVP-AEW541 on nasopharyngeal carcinoma bone metastasis, results showed that NVP-AEW541 significantly reduced bone metastasis and bone destruction. PMC10860326

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.38mL

2.28mL

1.14mL

22.75mL

4.55mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories